Allison W. Kurian, M.D., M.Sc.

Medical oncologist, Breast specialist, Cancer geneticist

Assistant Professor of Medicine (Oncology) and of Health Research and Policy at the Stanford University Medical Center
Allison W. Kurian, M.D., M.Sc. is an Assistant Professor of Medicine and of Health Research and Policy at Stanford University School of Medicine. She received her medical degree from Harvard Medical School, trained as a resident in Internal Medicine at the Massachusetts General Hospital, and completed her fellowship training in Medical Oncology along with a master’s degree in Epidemiology at Stanford University. As Associate Director of the Stanford Program in Clinical Cancer Genetics, and physician leader of the Stanford Women’s Cancer Genetics Clinic, her clinical practice centers on women at high risk for developing breast and gynecologic cancers. Dr. Kurian’s research focuses on the identification of women with elevated breast and gynecologic cancer risk, and on the development and evaluation of novel techniques for early cancer detection and risk reduction. Her research has been supported by the National Institutes of Health, the Komen Foundation, the American Society of Clinical Oncology, the California Breast Cancer Research Program, the Cancer Research and Prevention Foundation, the Robert Wood Johnson Foundation, and the Breast Cancer Research Foundation.

Breast Cancer Program

  • 900 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6004
Learn More About the Clinic Getting Here Make An Appointment

Women's Cancer Center

  • 900 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6004
Learn More About the Clinic Getting Here Make An Appointment

Cancer Genetics Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

M.Sc., Stanford University, Epidemiology (2006)

Board Certification: Medical Oncology, American Board of Internal Medicine (2005)

Fellowship: Stanford University School of Medicine (2005) CA

Residency: Massachusetts General Hospital (2002) MA

Internship: Massachusetts General Hospital (2000) MA

Medical Education: Harvard Medical School (1999) MA

B.A., Honors, Stanford University, Human Biology (1995)

Honors & Awards

Suzanne Pride Bryan Award for Breast Cancer Research, Stanford University Cancer Institute (2013)

Top 12 publications funded by the Epidemiology and Genomics Research Program, National Cancer Institute (2011)

New Clinical Investigator Award, Stanford University Cancer Institute (2011)

Translational Research Award, California Breast Cancer Research Program (2010)

Jan Weimer Faculty Chair for Breast Oncology, Stanford University Cancer Institute (2008)

Physician Faculty Scholars Award, Robert Wood Johnson Foundation (2008)

Cornelius L. Hopper Research Abstract Award, California Breast Cancer Research Program (2007)

BIRCWH K12 Scholar Award, National Institutes of Health (2006)

Young Investigator Award, American Society of Clinical Oncology (2005)

Fellowship Award, Cancer Research and Prevention Foundation (2005)

Fellowship Award, California Breast Cancer Research Program (2005)

Merit Award, American Society of Clinical Oncology (2004)

Administrative Appointments

Medical Oncology Investigator, Cancer Surveillance and Outcomes Research Team (CanSORT), University of Michigan School of Medicine, 2014

Oncology Consultant, Breast Cancer Working Group, Cancer Intervention and Surveillance Modeling Network (CISNET), National Cancer Institute, 2014

Associate Member, Canary Center at Stanford for Cancer Early Detection, 2014

Track Leader, Cancer Prevention and Epidemiology, Scientific Program Committee, American Society of Clinical Oncology, 2013

Director, Cancer Education Seminar, Stanford Division of Oncology, 2013

Panel on Clinical Guidelines Development for Breast Cancer Risk Reduction, National Comprehensive Cancer Network, 2013

Advisory Committee, California HealthCare Foundation, 2012

Scientific Program Committee, Cancer Prevention and Epidemiology, American Society of Clinical Oncology, 2011

Scientific Program Committee, Quality Care Symposium, American Society of Clinical Oncology, 2012

Scientific Program Committee, Genetic and Molecular Epidemiology, American Association for Cancer Research, 2011

Board of Directors, Santa Clara County, American Cancer Society, 2011

Panel on Clinical Guidelines Development for Genetic/ Familial Risk: Breast and Ovarian Cancer, National Comprehensive Cancer Network, 2009

Program Committee, Professional Development, American Society of Clinical Oncology, 2008

Career Development Subcommittee, American Society of Clinical Oncology, 2008

Associate Director, Stanford Clinical Cancer Genetics Program, 2007

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment.
Kurian, A. W., Hare, E. E., Mills, M. A., Kingham, K. E., McPherson, L., & Ford, J. M. (2014). Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. Journal of clinical oncology , 32(19), 2001-2009.

Breast cancer treatment across health care systems: linking electronic medical records and state registry data to enable outcomes research.
Kurian, A. W., Mitani, A., Desai, M., Yu, P. P., Seto, T., & Das, A. K. (2014). Breast cancer treatment across health care systems: linking electronic medical records and state registry data to enable outcomes research. Cancer, 120(1), 103-111.

Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007.
Kurian, A. W., Lichtensztajn, D. Y., Keegan, T. Hm., Leung, R. W., Shema, S. J., & Gomez, S. L. (2013). Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007. Breast cancer research and treatment, 137(1), 247-260.

Online Tool to Guide Decisions for BRCA1/2 Mutation Carriers
Kurian, A. W., Munoz, D. F., Rust, P., Schackmann, E. A., Smith, M., & Plevritis, S. K. (2012). Online Tool to Guide Decisions for BRCA1/2 Mutation Carriers. JOURNAL OF CLINICAL ONCOLOGY, 30(5), 497-506.

Oncoshare: lessons learned from building an integrated multi-institutional database for comparative effectiveness research.
Weber, S. C., Seto, T., Olson, C., Kenkare, P., Kurian, A. W., & Das, A. K. (2012). Oncoshare: lessons learned from building an integrated multi-institutional database for comparative effectiveness research. AMIA ... Annual Symposium proceedings / AMIA Symposium. AMIA Symposium, 2012, 970-978.

Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: Findings From the Breast Cancer Family Registry
Kurian, A. W., Gong, G. D., John, E. M., Johnston, D. A., Felberg, A., & Whittemore, A. S. (2011). Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: Findings From the Breast Cancer Family Registry. JOURNAL OF CLINICAL ONCOLOGY, 29(34), 4505-4509.

Survival Analysis of Cancer Risk Reduction Strategies for BRCA1/2 Mutation Carriers
Kurian, A. W., Sigal, B. M., & Plevritis, S. K. (2010). Survival Analysis of Cancer Risk Reduction Strategies for BRCA1/2 Mutation Carriers. JOURNAL OF CLINICAL ONCOLOGY, 28(2), 222-231.

Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups
Kurian, A. W., Fish, K., Shema, S. J., & Clarke, C. A. (2010). Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. BREAST CANCER RESEARCH, 12(6).

Second Primary Breast Cancer Occurrence According to Hormone Receptor Status
Kurian, A. W., McClure, L. A., John, E. M., Horn-Ross, P. L., Ford, J. M., & Clarke, C. A. (2009). Second Primary Breast Cancer Occurrence According to Hormone Receptor Status. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 101(15), 1058-1065.

Performance of BRCA1/2 mutation prediction models in Asian Americans
Kurian, A. W., Gong, G. D., Chun, N. M., Mills, M. A., Staton, A. D., & Ford, J. M. (2008). Performance of BRCA1/2 mutation prediction models in Asian Americans. JOURNAL OF CLINICAL ONCOLOGY, 26(29), 4752-4758.

A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer
Kurian, A. W., Newton Thompson, R., Gaw, A. F., Arai, S., Ortiz, R., & Garber, A. M. (2007). A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 25(6), 634-641.

Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging
Plevritis, S. K., Kurian, A. W., Sigal, B. M., Daniel, B. L., Ikeda, D. M., & Garber, A. M. (2006). Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 295(20), 2374-2384.

Histologic types of epithelial ovarian cancer: have they different risk factors?
Kurian, A. W., Balise, R. R., McGuire, V., & Whittemore, A. S. (2005). Histologic types of epithelial ovarian cancer: have they different risk factors?. GYNECOLOGIC ONCOLOGY, 96(2), 520-530.

Obesity and Mortality After Breast Cancer by Race/Ethnicity: The California Breast Cancer Survivorship Consortium
Kwan, M. L., John, E. M., Caan, B. J., Lee, V. S., Bernstein, L., & Wu, A. H. (2014). Obesity and Mortality After Breast Cancer by Race/Ethnicity: The California Breast Cancer Survivorship Consortium. AMERICAN JOURNAL OF EPIDEMIOLOGY, 179(1), 95-111.

Beyond barriers: fundamental 'disconnects' underlying the treatment of breast cancer patients' sexual health.
Halley, M. C., May, S. G., Rendle, K. A., Frosch, D. L., & Kurian, A. W. (2014). Beyond barriers: fundamental 'disconnects' underlying the treatment of breast cancer patients' sexual health. Culture, health & sexuality, 1-12.

Response.
Price, E. R., Hargreaves, J., Lipson, J. A., Sickles, E. A., Brenner, R. J., & Ikeda, D. M. (2014). Response. Radiology, 271(3), 927-8.

The California Breast Cancer Survivorship Consortium (CBCSC): prognostic factors associated with racial/ethnic differences in breast cancer survival
Wu, A. H., Gomez, S. L., Vigen, C., Kwan, M. L., Keegan, T. Hm., & Sposto, R. (2013). The California Breast Cancer Survivorship Consortium (CBCSC): prognostic factors associated with racial/ethnic differences in breast cancer survival. CANCER CAUSES & CONTROL, 24(10), 1821-1836.

A young woman with bilateral breast cancer: identifying a genetic cause and implications for management.
de Bruin, M. A., Ford, J. M., & Kurian, A. W. (2013). A young woman with bilateral breast cancer: identifying a genetic cause and implications for management. Journal of the National Comprehensive Cancer Network , 11(5), 512-517.

Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers.
Schackmann, E. A., Munoz, D. F., Mills, M. A., Plevritis, S. K., & Kurian, A. W. (2013). Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers. Familial cancer, 12(1), 65-73.

The California Breast Density Information Group: A Collaborative Response to the Issues of Breast Density, Breast Cancer Risk, and Breast Density Notification Legislation
Price, E. R., Hargreaves, J., Lipson, J. A., Sickles, E. A., Brenner, R. J., & Ikeda, D. M. (2013). The California Breast Density Information Group: A Collaborative Response to the Issues of Breast Density, Breast Cancer Risk, and Breast Density Notification Legislation. RADIOLOGY.

Information technology interventions to improve cancer care: a report from the American Society of Clinical Oncology Quality Care Symposium
Kurian, A. W., & Edge, S. B. (2013). Information technology interventions to improve cancer care: a report from the American Society of Clinical Oncology Quality Care Symposium. JOURNAL OF ONCOLOGY PRACTICE, 9(3).

A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk
Vinayak, S., Schwartz, E. J., Jensen, K., Lipson, J., Alli, B., & Kurian, A. W. (2013). A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. BREAST CANCER RESEARCH AND TREATMENT, electronic publication ahead of print, October 30.

Impact of breast cancer subtypes on three-year survival among adolescent and young adult women
Keegan, T. Hm., Press, D. J., Tao, L., DeRouen, M. C., Kurian, A. W., & Gomez, S. L. (2013). Impact of breast cancer subtypes on three-year survival among adolescent and young adult women. BREAST CANCER RESEARCH, 15(5).

A Population-Based Observational Study of First-Course Treatment and Survival for Adolescent and Young Adult Females with Breast Cancer.
DeRouen, M. C., Gomez, S. L., Press, D. J., Tao, L., Kurian, A. W., & Keegan, T. Hm. (2013). A Population-Based Observational Study of First-Course Treatment and Survival for Adolescent and Young Adult Females with Breast Cancer. JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY, 2(3).

Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients
Kwong, A., Ng, E. Ko., Law, F. Bf., Wong, H. N., Wa, A., & Ma, E. Sk. (2012). Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients. BREAST CANCER RESEARCH AND TREATMENT, 136(3), 931-933.

Identification of BRCA1/2 Founder Mutations in Southern Chinese Breast Cancer Patients Using Gene Sequencing and High Resolution DNA Melting Analysis
Kwong, A., Ng, E. K. O., Wong, C. L. P., Law, F. B. F., Au, T., & Ma, E. S. K. (2012). Identification of BRCA1/2 Founder Mutations in Southern Chinese Breast Cancer Patients Using Gene Sequencing and High Resolution DNA Melting Analysis. PLOS ONE, 7(9).

Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations
de Bruin, M. A., Kwong, A., Goldstein, B. A., Lipson, J. A., Ikeda, D. M., & Kurian, A. W. (2012). Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. FAMILIAL CANCER, 11(3), 429-439.

A Simulation Model to Predict the Impact of Prophylactic Surgery and Screening on the Life Expectancy of BRCA1 and BRCA2 Mutation Carriers
Sigal, B. M., Munoz, D. F., Kurian, A. W., & Plevritis, S. K. (2012). A Simulation Model to Predict the Impact of Prophylactic Surgery and Screening on the Life Expectancy of BRCA1 and BRCA2 Mutation Carriers. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 21(7), 1066-1077.

Age-Specific Incidence of Breast Cancer Subtypes: Understanding the BlackWhite Crossover
Clarke, C. A., Keegan, T. Hm., Yang, J., Press, D. J., Kurian, A. W., & Lacey, J. V. (2012). Age-Specific Incidence of Breast Cancer Subtypes: Understanding the BlackWhite Crossover. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 104(14), 1094-1101.

Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines
Powell, A. A., Talasaz, Aa. H., Zhang, H., Coram, M. A., Reddy, A., & Jeffrey, S. S. (2012). Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines. PLOS ONE, 7(5).

Patient, Hospital, and Neighborhood Factors Associated with Treatment of Early-Stage Breast Cancer among Asian American Women in California
Gomez, S. L., Press, D. J., Lichtensztajn, D., Keegan, T. Hm., Shema, S. J., & Kurian, A. W. (2012). Patient, Hospital, and Neighborhood Factors Associated with Treatment of Early-Stage Breast Cancer among Asian American Women in California. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 21(5), 821-834.

Accuracy of BRCA1/2 Mutation Prediction Models for Different Ethnicities and Genders: Experience in a Southern Chinese Cohort
Kwong, A., Wong, C. Hn., Suen, D. Tk., Co, M., Kurian, A. W., & Ford, J. M. (2012). Accuracy of BRCA1/2 Mutation Prediction Models for Different Ethnicities and Genders: Experience in a Southern Chinese Cohort. WORLD JOURNAL OF SURGERY, 36(4), 702-713.

In reply to "Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: More Trouble With Phenocopies" by Evans et al
Kurian, A. W., & Whittemore, A. S. (2012). In reply to "Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: More Trouble With Phenocopies" by Evans et al. JOURNAL OF CLINICAL ONCOLOGY, 30.

Genetic Polymorphisms as Predictors of Breast Cancer Risk
de Bruin, M. A., Ford, J. M., & Kurian, A. W. (2012). Genetic Polymorphisms as Predictors of Breast Cancer Risk. CURRENT BREAST CANCER REPORTS.

Occurrence of breast cancer subtypes in adolescent and young adult women
Keegan, T. Hm., DeRouen, M. C., Press, D. J., Kurian, A. W., & Clarke, C. A. (2012). Occurrence of breast cancer subtypes in adolescent and young adult women. BREAST CANCER RESEARCH, 14(2).

A Prospective Study of Total Gastrectomy for CDH1-Positive Hereditary Diffuse Gastric Cancer
Chen, Y., Kingham, K., Ford, J. M., Rosing, J., Van Dam, J., & Norton, J. A. (2011). A Prospective Study of Total Gastrectomy for CDH1-Positive Hereditary Diffuse Gastric Cancer. ANNALS OF SURGICAL ONCOLOGY, 18(9), 2594-2598.

Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry
Telli, M. L., Chang, E. T., Kurian, A. W., Keegan, T. Hm., McClure, L. A., & Gomez, S. L. (2011). Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. BREAST CANCER RESEARCH AND TREATMENT, 127(2), 471-478.

Hereditary cancer: counseling women at risk
Lebensohn, A. P., Kingham, K. E., Chun, N. M., & Kurian, A. W. (2011). Hereditary cancer: counseling women at risk. CONTEMPORARY OBSTETRICS AND GYNECOLOGY, 56(4).

High-resolution melting analysis for rapid screening of BRCA2 founder mutations in Southern Chinese breast cancer patients
Kwong, A., Ng, E. Ko., Law, F. Bf., Wong, L. P., To, M. Y., & Ma, E. Sk. (2010). High-resolution melting analysis for rapid screening of BRCA2 founder mutations in Southern Chinese breast cancer patients. BREAST CANCER RESEARCH AND TREATMENT, 122(2), 605-607.

Genetic/familial high-risk assessment: breast and ovarian.
Daly, M. B., Axilbund, J. E., Buys, S., Crawford, B., Farrell, C. D., & Weitzel, J. N. (2010). Genetic/familial high-risk assessment: breast and ovarian. Journal of the National Comprehensive Cancer Network , 8(5), 562-594.

Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California
Gomez, S. L., Lichtensztajn, D., Kurian, A. W., Telli, M. L., Chang, E. T., & Clarke, C. A. (2010). Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California. JOURNAL OF CLINICAL ONCOLOGY, 28(10), E155-E157.

BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications
Kurian, A. W. (2010). BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 22(1), 72-78.

Performance of Prediction Models for BRCA Mutation Carriage in Three Racial/Ethnic Groups: Findings from the Northern California Breast Cancer Family Registry
Kurian, A. W., Gong, G. D., John, E. M., Miron, A., Felberg, A., & Whittemore, A. S. (2009). Performance of Prediction Models for BRCA Mutation Carriage in Three Racial/Ethnic Groups: Findings from the Northern California Breast Cancer Family Registry. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 18(4), 1084-1091.

In reply to 'Tailoring BRCRAPRO to Asian Americans?' by S. Chen et al
Kurian, A. W., Whittemore, A. S., & Ford, J. M. (2009). In reply to 'Tailoring BRCRAPRO to Asian Americans?' by S. Chen et al. JOURNAL OF CLINICAL ONCOLOGY, 27.

The Decline in Breast Cancer Incidence: Real or Imaginary?
Kurian, A. W., Clarke, C. A., & Carlson, R. W. (2009). The Decline in Breast Cancer Incidence: Real or Imaginary?. CURRENT ONCOLOGY REPORTS, 11(1), 21-28.

Statins May Reduce Breast Cancer Risk, Particularly Hormone Receptor-Negative Disease.
Vinayak, S., & Kurian, A. W. (2009). Statins May Reduce Breast Cancer Risk, Particularly Hormone Receptor-Negative Disease. Current breast cancer reports, 1(3), 148-156.

Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers
Staton, A. D., Kurian, A. W., Cobb, K., Mills, M. A., & Ford, J. M. (2008). Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. FAMILIAL CANCER, 7(2), 179-186.

Magnetic resonance galactography: A feasibility study in women with prior atypical breast duct cytology
Kurian, A. W., Hartman, A.-R., Mills, M. A., Logan, L. J., Sawyer, A. M., & Daniel, B. L. (2008). Magnetic resonance galactography: A feasibility study in women with prior atypical breast duct cytology. BREAST JOURNAL, 14(2), 211-214.

A carrier of both MEN1 and BRCA2 mutations: case report a-lid review of the literature
Ghataorhe, P., Kurian, A. W., Pickart, A., Trapane, P., Norton, J. A., & Ford, J. M. (2007). A carrier of both MEN1 and BRCA2 mutations: case report a-lid review of the literature. CANCER GENETICS AND CYTOGENETICS, 179(2), 89-92.

CDH1 truncating mutations in the E-cadherin gene - An indication for total gastrectomy to treat hereditary diffuse gastric cancer
Norton, J. A., Ham, C. M., Van Dam, J., Jeffrey, R. B., Longacre, T. A., & Ford, J. M. (2007). CDH1 truncating mutations in the E-cadherin gene - An indication for total gastrectomy to treat hereditary diffuse gastric cancer. ANNALS OF SURGERY, 245(6), 873-879.

Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage
Ghanouni, P., Kurian, A. W., Margolis, D., Hartman, A.-R., Mills, M. A., & Daniel, B. L. (2007). Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage. BREAST JOURNAL, 13(3), 281-286.

Biomedical terahertz imaging with a quantum cascade laser
Kim, S. M., Hatami, F., Harris, J. S., Kurian, A. W., Ford, J., & Harris, G. (2006). Biomedical terahertz imaging with a quantum cascade laser. APPLIED PHYSICS LETTERS, 88(15).

Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage
Kurian, A. W., Hartman, A. R., Mills, M. A., Ford, J. M., Daniel, B. L., & Plevritis, S. K. (2005). Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. HEALTH EXPECTATIONS, 8(3), 221-233.

Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk
Kurian, A. W., Mills, M. A., Jaffee, M., Sigal, B. M., Chun, N. M., & Hartman, A. R. (2005). Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 14(5), 1082-1089.

Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma
Hartman, A. R., Daniel, B. L., Kurian, A. W., Mills, M. A., Nowels, K. W., & Plevritis, S. K. (2004). Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. CANCER, 100(3), 479-489.